Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPT NASDAQ:IMCR NASDAQ:RGNX NASDAQ:TVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$12.82-0.7%$12.01$3.98▼$13.68$1.97B1.931.67 million shs1.43 million shsIMCRImmunocore$33.42-1.2%$34.04$23.15▼$39.33$1.70B0.77267,557 shs553,886 shsRGNXREGENXBIO$9.03-2.5%$8.77$5.03▼$13.15$467.76M1.17496,685 shs295,868 shsTVTXTravere Therapeutics$23.65+3.9%$18.03$12.91▼$28.69$2.03B0.792.63 million shs2.01 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-1.30%+2.38%-1.00%+23.30%+181.26%IMCRImmunocore-1.77%-7.60%+2.83%+6.66%+2.45%RGNXREGENXBIO+1.87%-6.37%+4.99%+8.05%-27.32%TVTXTravere Therapeutics-1.04%+5.22%+20.99%+58.02%+59.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$12.82-0.7%$12.01$3.98▼$13.68$1.97B1.931.67 million shs1.43 million shsIMCRImmunocore$33.42-1.2%$34.04$23.15▼$39.33$1.70B0.77267,557 shs553,886 shsRGNXREGENXBIO$9.03-2.5%$8.77$5.03▼$13.15$467.76M1.17496,685 shs295,868 shsTVTXTravere Therapeutics$23.65+3.9%$18.03$12.91▼$28.69$2.03B0.792.63 million shs2.01 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-1.30%+2.38%-1.00%+23.30%+181.26%IMCRImmunocore-1.77%-7.60%+2.83%+6.66%+2.45%RGNXREGENXBIO+1.87%-6.37%+4.99%+8.05%-27.32%TVTXTravere Therapeutics-1.04%+5.22%+20.99%+58.02%+59.57%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.88Moderate Buy$12.38-3.47% DownsideIMCRImmunocore 2.45Hold$56.8970.22% UpsideRGNXREGENXBIO 2.83Moderate Buy$28.38214.23% UpsideTVTXTravere Therapeutics 2.87Moderate Buy$34.2044.61% UpsideCurrent Analyst Ratings BreakdownLatest RGNX, ADPT, TVTX, and IMCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025TVTXTravere TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$20.00 ➝ $25.009/11/2025TVTXTravere TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$27.00 ➝ $35.009/10/2025TVTXTravere TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$35.009/10/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.009/8/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$52.009/8/2025RGNXREGENXBIOHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.009/4/2025IMCRImmunocoreZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/3/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.008/28/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $47.008/25/2025IMCRImmunocoreJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$48.008/19/2025RGNXREGENXBIOHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$178.96M10.91N/AN/A$1.37 per share9.36IMCRImmunocore$310.20M5.43N/AN/A$7.20 per share4.64RGNXREGENXBIO$83.33M5.47N/AN/A$5.24 per share1.72TVTXTravere Therapeutics$233.18M9.04N/AN/A$0.76 per share31.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$159.49M-$0.820.00N/AN/A-59.07%-60.93%-23.03%11/6/2025 (Estimated)IMCRImmunocore-$51.09M-$0.400.00N/AN/A-5.70%-5.40%-1.93%11/5/2025 (Estimated)RGNXREGENXBIO-$227.10M-$3.440.00N/AN/A-112.70%-66.95%-34.14%11/5/2025 (Estimated)TVTXTravere Therapeutics-$321.55M-$2.040.00N/AN/A-50.64%-717.68%-30.69%10/30/2025 (Estimated)Latest RGNX, ADPT, TVTX, and IMCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025IMCRImmunocore-$0.21-$0.20+$0.01-$0.20$122.96 million$130.65 million8/7/2025Q2 2025RGNXREGENXBIO-$1.13-$1.38-$0.25-$1.38$40.87 million$21.36 million8/6/2025Q2 2025TVTXTravere Therapeutics-$0.28-$0.14+$0.14-$0.14$100.18 million$94.84 million8/5/2025Q2 2025ADPTAdaptive Biotechnologies-$0.24-$0.17+$0.07-$0.17$49.40 million$49.94 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ATVTXTravere TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A2.842.75IMCRImmunocore1.015.895.86RGNXREGENXBION/A3.133.13TVTXTravere Therapeutics9.502.001.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%IMCRImmunocore84.50%RGNXREGENXBIO88.08%TVTXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies6.40%IMCRImmunocore10.40%RGNXREGENXBIO12.79%TVTXTravere Therapeutics4.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790152.27 million142.53 millionOptionableIMCRImmunocore32050.39 million45.15 millionOptionableRGNXREGENXBIO37050.51 million44.05 millionOptionableTVTXTravere Therapeutics46089.14 million85.40 millionOptionableRGNX, ADPT, TVTX, and IMCR HeadlinesRecent News About These CompaniesTravere Therapeutics (NASDAQ:TVTX) Price Target Raised to $25.00September 14 at 10:43 AM | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Given New $25.00 Price Target at Stifel NicolausSeptember 14 at 3:59 AM | americanbankingnews.comTravere Therapeutics, Inc. $TVTX Shares Sold by AQR Capital Management LLCSeptember 14 at 3:24 AM | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Shares Down 4.8% - Should You Sell?September 13, 2025 | marketbeat.comWells Fargo & Company Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $35.00September 13, 2025 | marketbeat.comWoodline Partners LP Sells 884,278 Shares of Travere Therapeutics, Inc. $TVTXSeptember 13, 2025 | marketbeat.comWells Fargo & Company Increases Travere Therapeutics (NASDAQ:TVTX) Price Target to $35.00September 13, 2025 | americanbankingnews.comTravere Therapeutics: Buy Rating On Back Of Filspari Expansion Towards FSGSSeptember 12, 2025 | seekingalpha.comHC Wainwright Reaffirms Buy Rating for Travere Therapeutics (NASDAQ:TVTX)September 12, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Reaches New 1-Year High - Here's What HappenedSeptember 12, 2025 | marketbeat.comTVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDASeptember 11, 2025 | zacks.comTravere Therapeutics price target raised to $35 from $27 at Wells FargoSeptember 11, 2025 | msn.comTravere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate SubsideSeptember 11, 2025 | insidermonkey.comStrength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?September 11, 2025 | zacks.comTravere rises as FDA says no AdCom required for Filspari label expansionSeptember 10, 2025 | msn.comTravere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug ApplicationSeptember 10, 2025 | msn.comTravere Therapeutics (TVTX) Awaits FDA Decision as FILSPARI Shows Promising Clinical ResultsSeptember 10, 2025 | finance.yahoo.comTravere: No AdCom, No Problem - Targeting Big Revenues With FSGS ApprovalSeptember 10, 2025 | seekingalpha.comTraders Purchase High Volume of Call Options on Travere Therapeutics (NASDAQ:TVTX)September 10, 2025 | marketbeat.comWhy Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year HighSeptember 10, 2025 | investors.comTravere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGSSeptember 10, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRGNX, ADPT, TVTX, and IMCR Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$12.82 -0.09 (-0.70%) Closing price 04:00 PM EasternExtended Trading$12.91 +0.09 (+0.70%) As of 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Immunocore NASDAQ:IMCR$33.42 -0.39 (-1.15%) Closing price 04:00 PM EasternExtended Trading$33.46 +0.03 (+0.10%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.REGENXBIO NASDAQ:RGNX$9.03 -0.23 (-2.48%) Closing price 04:00 PM EasternExtended Trading$9.39 +0.36 (+3.99%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.Travere Therapeutics NASDAQ:TVTX$23.65 +0.88 (+3.86%) Closing price 04:00 PM EasternExtended Trading$23.82 +0.17 (+0.74%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? The Side of Rate Cuts Nobody Is Telling You About Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Dave & Buster’s Stock: Is Now the Time to Make a PLAY? Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
